Trial Profile

Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Zanzalintinib (Primary)
Indications Fibrosarcoma; Haemangiosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma
Focus Adverse reactions

Most Recent Events

07 Aug 2025 Planned End Date changed from 31 Jan 2031 to 31 Mar 2031.
07 Aug 2025 Planned primary completion date changed from 12 Feb 2026 to 12 Apr 2026.
07 Aug 2025 Planned initiation date changed from 31 Jul 2025 to 30 Sep 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com